Dailiport 0.5 mg Noregur - norska - Statens legemiddelverk

dailiport 0.5 mg

sandoz - københavn - takrolimusmonohydrat - depotkapsel, hard - 0.5 mg

Dailiport 1 mg Noregur - norska - Statens legemiddelverk

dailiport 1 mg

sandoz - københavn - takrolimusmonohydrat - depotkapsel, hard - 1 mg

Dailiport 5 mg Noregur - norska - Statens legemiddelverk

dailiport 5 mg

sandoz - københavn - takrolimusmonohydrat - depotkapsel, hard - 5 mg

Calquence Evrópusambandið - norska - EMA (European Medicines Agency)

calquence

astrazeneca ab - acalabrutinib - leukemi, lymfocytisk, kronisk, b-celle - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Dailiport 2 mg Noregur - norska - Statens legemiddelverk

dailiport 2 mg

sandoz - københavn - takrolimusmonohydrat - depotkapsel, hard - 2 mg

Atorvastatin Accord 10 mg Noregur - norska - Statens legemiddelverk

atorvastatin accord 10 mg

accord healthcare b.v. - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 10 mg

Atorvastatin Accord 20 mg Noregur - norska - Statens legemiddelverk

atorvastatin accord 20 mg

accord healthcare b.v. - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 20 mg

Atorvastatin Accord 40 mg Noregur - norska - Statens legemiddelverk

atorvastatin accord 40 mg

accord healthcare b.v. - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 40 mg

Atorvastatin Accord 80 mg Noregur - norska - Statens legemiddelverk

atorvastatin accord 80 mg

accord healthcare b.v. - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 80 mg

Brukinsa Evrópusambandið - norska - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastiske midler - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).